-
Product Insights
Dementia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Dementia- Global Clinical Trials Review, 2025" provides an overview of Dementia Clinical trials scenario. This report provides top line data relating to the clinical trials on Dementia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Camrelizumab...
-
Sector Analysis
Frontotemporal Dementia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Frontotemporal Dementia therapeutics. • In 2024, more than 700,000 diagnosed prevalent cases of FTD are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for FTD. • There are currently no approved therapies for FTD in the market. • The FTD pipeline is notably sparse, with no assets in the pre-registration stage, a single asset in Phase III development. • Over the past 10 years,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal...
-
Product Insights
Frontotemporal Dementia (FTD) - Drugs In Development, 2024
Empower your strategies with our Frontotemporal Dementia (FTD) – Drugs In Development, 2024 report and make more profitable business decisions. Frontotemporal dementia (FTD) encompasses various brain disorders leading to progressive damage in the frontal and temporal lobes. It manifests in distinct ways: behavioral changes, language difficulties, or movement impairments. Symptoms range from altered social conduct, lack of empathy, and impulsivity to language struggles or motor coordination issues. FTD's exact cause remains unclear, but abnormal protein deposits in the brain are implicated....
-
Product Insights
Dementia Associated With Alzheimer's Disease - Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
Lewy Body Dementia - Drugs In Development, 2024
Empower your strategies with our Lewy Body Dementia – Drugs In Development, 2024 report and make more profitable business decisions. Lewy body dementia (LBD) is a progressive neurodegenerative disorder characterized by the abnormal accumulation of alpha-synuclein protein deposits (Lewy bodies) in the brain. This condition shares similarities with both Alzheimer's disease and Parkinson's disease, presenting a complex spectrum of symptoms that affect cognition, movement, behavior, and autonomic functions. LBD manifests through various symptoms that may fluctuate in severity, including cognitive changes...
-
Product Insights
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) - Drugs In Development, 2024
Empower your strategies with our Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions. Corticobasal degeneration (CBD) or corticobasal syndrome (CBS) is a rare neurological disorder that causes brain cells to die or become damaged. CBD is a form of frontotemporal degeneration, a dementia that involves the loss of cognitive functions that can gradually lead to worsening of movement, speech, memory, and swallowing. Symptoms include a clumsy or useless hand, muscle stiffness,...
-
Product Insights
Vascular Dementias - Drugs In Development, 2024
Empower your strategies with our Vascular Dementias – Drugs In Development, 2024 report and make more profitable business decisions. Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. Vascular dementia can be caused by ischemic or hemorrhagic infarcts affecting multiple brain areas, including the anterior cerebral artery territory, the parietal lobes, or...
-
Sector Analysis
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Report Overview Lewy body dementia (LBD) is a common type of dementia that happens when clumps of proteins called Lewy bodies build up in the brain. They damage parts of the brain that affect cognition, behavior, movement, and sleep. Lewy body intracellular inclusions result from the aggregation of misfolded α-synuclein. There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.